Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, announces the completion of the previously announced planned divestiture of its Parcus Medical business to Medacta Group SA. “The sale of Parcus marks a critical step forward as we achieve the goals of our previously announced strategic review. We are better positioned than ever to fully focus on our core hyaluronic acid technology and advance our differentiated and growing Regenerative Solutions portfolio.” said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika Therapeutics.
Read the full article: Anika Completes Divestiture of Parcus Medical //
Source: https://www.globenewswire.com/news-release/2025/03/07/3038818/28467/en/Anika-Completes-Divestiture-of-Parcus-Medical.html